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1. Introduction 
1.1 The structure of cyclophosphamide (CY) and its active metabolites acrolein (ACR) 
and phosphoramide mustard (PM)  
Cyclophosphamide (CY), an alkylating compound is commonly used as a cytoreductive 
agent in the treatment of cancer ( blood, breast, ovary) because of its ability to interfere with 
DNA synthesis and its pharmacological action on dividing cells (Ben Efraim 2001). Its action 
is however more complex since it exerts a strong influence on the immune system. Studies 
on cyclophosphamide are conducted for a long time, but its effect on macrophages (Mf) was 
not yet definite, therefore this study was attempted. 
CY is in vitro inactive by itself, and is converted in vivo into two ultimately biologically 
active alkylating metabolites: phosphoramide mustard (PM) and acrolein (ACR).The first 
step of that complicated pathway of CY metabolism occurs in the liver and results in the 
formation of derivative hydroperoxycyclophosphamide and then it is followed by several 
enzymatic reactions that format carbonamide, aldehyde and carboxylacide inactive 
structures or lead to non-enzymatic formation of phosphoramide mustard and acrolein,  
active metabolites of cyclophosphamide which were tested in our immune research. Instead 
of highly unstable phosphoramide mustard (PM), we used nitrogen mustard (NM, 
mechlorethamine) (see Fig 1.) which is structurally and functionally related to PM, 
previously shown in vitro and in vivo to have the same activity as CY (Bryniarski et al. 1996).  
  
Fig. 1. The chemical structure of cyclophosphamide and nitrogen mustard 
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2. Differences of CY dose treatment used in the treatment of malignant 
diseases and autoimmune diseases in comparison to immune regulation  
Immunoregulatory function of CY is observed in doses 20-100 mg/kg in mice, which can be 
calculated in human treatment as below 2mg/kg (less than 100 mg/m2). The higher doses of 
cyclophosphamide above 100mg/m2 (2-3mg/kg) in humans mainly used in several pulses 
or as prolonged treatments are used in anticancer therapy of peripheral blood cancers and 
lymphoma (Audia et al. 2007; Vitolo et al. 2008) as well as in metastases of breast, ovarian 
and bronchial cancers (Snowden et al. 1997; Audia et al. 2007; Burger 2007) trophoblastic 
tumors (Cole et al. 2008), leiomyosarcoma (Durhan et al. 2009), pheochromocytoma (Adjalle 
et al. 2009), rhabdomyosarcoma (Breitfeld & Mayer 2005). 
Much higher doses of CY (50mg/kg per 3 days) are proposed to be used in treatment of 
Graft Versus Host Disease (GVHD) after allogenic hematopoetic stem cells transplantation 
(alloHSCT) for treatment of hematologic malignancies (Luznik & Fuchs 2010). Post-
transplantation  CY promotes tolerance in alloreactive host and donor T cells leading to 
suppression of both graft rejection and GVHD after alloHSCT. 
In autoimmune diseases like sclerosis multiplex (MS),  lupus nephritis or immune mediated 
neuropathies,  CY is the medicament used for pulsed first treatment as well for the 
retreatment in  several doses mainly higher than 100 up to 1600 mg/m2. It is proved that CY 
treatment seems to give better therapeutic effect in patients in earlier stages of MS where 
inflammation predominates over degenerative processes in the central nervous system 
(CNS). There is no evidence of efficacy in primary progressive MS or later stages of 
secondary progressive MS. In  these high doses of CY therapy, patients show low pro-
inflammatory cytokine secretion which activates anti-inflammatory cytokine secretion, what 
is suggested in an elegant review by Weiner and Cohen as one of curative effects in MS 
neurodegenerative disease (Weiner & Cohen 2002). That high dose treatment can express 
quite a different suppressor effect on the immune system mediated by B and T lymphocytes 
that mediate two branches of humoral and cellular immune responses. High doses of CY 
used for the treatment of malignant or autoimmune diseases express more toxic effects on 
the immune system by elimination of different currently activated subpopulations of 
immune cells and lead to inhibition of inflammatory reactions which diminish the formation 
of degenerative lesions. 
Cyclophosphamide is commonly used in multiagent chemotherapy rather than intravenous 
(i.v.) monotherapy for treatment of malignancies,  therefore its dose  can be relatively lesser 
than in case of single use (because of the effect of summarizing or multiplying of drug 
activity and toxicity). It also must be taken into consideration what kind of regulatory 
therapeutic effect is desired – the activating effect based on elimination of natural 
suppression in case of low doses treatment, or suppressor effect on the immune cells, 
maintained mainly by cytotoxic effect which appears in case of treatment with high doses of 
CY. It is estimated that the therapeutic dose of endoxan equals about 25-50% of toxic dose. 
The control of unwanted and unexpected toxic effects must be also taken into  consideration 
in case of establishing  any kind of CY therapy. Between the most frequent unwanted toxic 
effects observed in case of CY treatment is gonadal disfunction observed in man in a lower 
cumulative dose in man (60 g/m2) less expressed in female (Vitolo et al. 2008). Moreover, 
apart from alopecia and nausea, the other toxic effects are infections and hemorrhagic 
cystitis. There is also an increased risk of cancer and bladder toxicity which appears in the 
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cumulative life-time dose exceeding  80-100 g (which is about 50 doses of 1000 mg/m2 
during life-time) (Weinar & Cohen 2002) . 
3. Immunoregulatory activities of cyclophosphamide treatment – The 
evidence performed in mice by the low dose cyclophosphamide treated 
macrophages  
Macrophages (Mf) carry out the fundamental protective function of phagocyting and killing 
invading organisms and release a vast number of factors involved in host defense and 
inflammation. Moreover they play a critical role in the induction, regulation and expression 
of both cellular and humoral responses. These highly diversified functions are accompanied 
by heterogeneous morphology and biochemical and phenotypical characteristics.  
3.1 Methods for estimation of macrophage activity in innate and in adaptive humoral 
and cellular immune responses 
My experimental studies were aimed at the establishing the influence of low dose of CY 
treatment (20-50 mg/kg) on the macrophages (Mf) – the important cells involved in an 
innate and humoral or cellular adaptive immune responses in mice. The innate immune 
response was measured by both the capacity of reactive oxygen intermediates production 
and secretion by phagocytic activating macrophages and by the ability of production of 
proinflammatory cytokines (IL-1, IL-6 and TNF-) (Marcinkiewicz  et al. 1994). The ability 
of cyclophosphamide treated Mf (MfCY) to secrete regulatory cytokine (proinflammatory 
IL-12 and inhibitory TGF- and IL-10) was  also tested in their supernatant over the Mf 
culture and was  estimated  by ELISA (total concentration) (Bryniarski 2004 & 2009), or in 
bioassays which utilize proliferation effect of particular cytokine by cytokine-dependent cell 
lines and measures exclusively bioactive form of particular cytokine (Marcinkiewicz et al. 
1994 & Bryniarski et al. 1996). The cell surface markers of tested Mf were estimated 
cytofluorimetrically in FACS (Szczepanik et al. 1993 & Bryniarski et al. 2009), but the 
phenotypical differences between functionally differentiated macrophages were estimated 
by measuring  the pattern of esterase activity (Czajkowska et al. 1995).  
The induction of cellular response was tested in contact hypersensitivity against TNP/PCL 
hapten (Szczepanik et al. 1993, Bryniarski et al. 2004) which activates CD4 Th1 
subpopulation of lymphocytes and macrophages and is classified by Pichler as a classical 
type IVa delayed type hypersensitivity (Lerch & Pichler 2004; Posadas & Pichler 2007). 
Humoral activity against corpuscular antigen was  tested in plaque forming assay (PFA) 
from Mf pulsed with sheep red blood cells and cultured 4 days in the presence of naïve B 
cells. The antigen presenting activity was estimated as a number of plaque forming cells 
PFC/106 splenocytes (Bryniarski et al. 2004).  
3.2 Treatment of donors of macrophages with low dose of CY uncovers the 
subpopulation of peritoneal macrophages that induce CHS response in mice  
Application of hapten on the skin is a classical way to immunize for contact sensitivity 
reaction, but animals can also be sensitized by subcutaneous injection of hapten substituted 
peritoneal macrophages. However, if haptenated macrophages are injected i.v. a long-lasting 
unresponsiveness ensues, in which the activity of Th1 immune effector lymphocytes is 
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obliterated by simultaneously recruited CD8+suppressor cells. When subsequently skin 
sensitized, such animals have significantly diminished CHS reactions. Moreover this state of 
unresponsiveness can be adoptively transferred to naïve syngeneic animals by lymphoid cells.  
The CHS reaction to trinitrophenyl (TNP/PCL) hapten is activated by CD4 Th1 
lymphocytes which recognize TNP/PCL hapten on the surface of MHC class II expressed by 
hapten-labeled macrophages. After 5 days the sensitized recipients of TNP-Mf are able to 
reduce the CHS reaction when challenged by applying a very low dose of the same hapten 
(TNP/PCL) on the ear skin. The CHS reaction develops 24 h after challenge (with hapten) as 
ear swelling CHS response and is measured with the engineering micrometer and expressed 
in units of ear swelling (Szczepanik et al. 1993). When the donors of macrophages are 
injected intravenously (i.v.) with low dose of cyclophosphamide (20-100mg/kg) a day 
before cell harvesting, then the cells are labeled with hapten and injected i.v. into naïve 
recipients instead of unresponsiveness strong contact hypersensitivity develops 24 h after 
the challenge with the same hapten. Moreover it was shown that in vivo CY treatment 
activates strong functional diversification of macrophage subpopulations in mice. Thus 
result of in vivo CY treatment, hapten-conjugated Mf (TNP-MfCY) when injected i.v. into 
naïve recipients TNP-MfCY activate strong contact hypersensitivity (CHS) reaction against 
hapten, instead of unresponsiveness induced by TNP-Mf mediated by CD8+ T suppressor 
lymphocytes, which inhibit hapten specific CHS response (Fig. 2).  
 
CBA/J mice were injected i.v. with 1 x 106 TNP-Mf from donors treated (group C) or untreated (group 
B) with CY. Seven days later these animals  and a group of naïve mice (group A) were skin sensitized 
with PCL and tested for contact hypersensitivity (CHS) after additional 4 days. Statistical significance 
group B ve groups A & C p<0.002 
Fig. 2. Peritoneal macrophages from cyclophosphamide-treated mice do not induce 
suppressor cells. 
It was shown by us that CY sensitive subpopulation of peritoneal macrophages responsible for 
induction of suppressor cells has higher density when separated in discontinuous gradient of 
Ficoll than population activating CHS response. Moreover it has also strong adherent and 
higher phagocyting properties and has high expression of FcRI and FcRII  (33-44%) in 
comparison to the low density cell fraction, which is CY resistant. The latest fraction of cells is 
weakly phagocytic and adherent, has less FcR (22-26%). It is widely known that antigen 
presenting cells (APC) are macrophages, dendritic cells and B lymphocytes. First two 
populations can phagocyte, but last is inactive in this activity. For two reasons it seems 
unlikely that previously described light fraction of cells are contaminated with dendritic cells. 
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First almost all of them labeled with macrophage specific F4/80 antibody, second, as shown 
previously by Steinman and Cohn peritoneal exudate cells induced by thioglycolate, although 
contaminated by several cell types do not contain dendritic cells (Szczepanik et al. 1993). Both 
subpopulations of tested macrophages express no significant differences in Mac-1 (30-50%) 
and Mac-3 (33-46%) markers and no differences were found between CY-treated and 
untreated mice in a surface expression of I-A (7-14%) and I-E (3-6%) antigens. We were not 
able to associate the differences in surface markers expression in both populations of 
macrophages with variety of their bioactivity and immune function (Szczepanik et al. 1993). 
We also found that Mf CY express slightly higher percentage of molecules important in the 
stimulation of  phagocytosis (CD14 and CD23) and molecules basic for activation of antigen-
presenting immune response (CD80/CD86 and MHC class II) in comparison to control oil-
induced peritoneal macrophages. Results are shown in Table 1.  
 
Macrophages CD23/Mac3 CD80/Mac3 CD86/Mac3 CD14/Mac3 DR/Mac3 
Mf 62.0 50.0 51.6 59.3 45.4 
Mf CY 
[50mg/kg] 
73.7 68.4 71.6 71.7 59.0 
Oil-induced macrophages were labeled for direct immunofluorescence with monoclonal antibodies 
specific against specific macrophage antigen (Mac3-FITC)  and  cell surface markers (CD23-PE, CD80-
PE, CD86-PE, CD14-PE, MHCII DR-PE). Results are expressed as a percent of double positive cells. The 
measurement was performed on the FASC Cytoron-Absolute.  
Table 1. Expression of selected surface markers on macrophages isolated from oil-induced 
peritoneal cavity from donors treated or not treated with cyclophosphamide in dose 50 
mg/kg.  
In following experiment we have shown (Bryniarski et al. 2009) that cyclophosphamide in vivo 
as well as its both tested metabolic products in vitro - acrolein (ACR) and mechloretamine  
(NM) (nitrogen mustard – an analogue of phosphoramide mustard) make TNP-substituted Mf 
(TNP-Mf)  immunogenic for the induction of CHS response. The results are shown in Table 2. 
  
Group Mice injected with CHS response [U x 10-2 mm] ± SD 
A TNP-Mf 0.2 ± 0.84
B TNP-Mf CY 4.8 ± 0.68
C TNP-Mf ACR 5.3 ± 1.12
D TNP-Mf NM 5.2 ± 0.66
E TNP-Mf ACR & NM 5.5 ± 0.90
The following abbreviations are used: TNP-Mf - TNP substituted Mf from control mice; TNP-Mf CY - 
Mf from mice treated with CY (50 mg/kg); TNP-Mf ACR – normal Mf treated in vitro with 10-7 M ACR; 
TNP-Mf NM -  normal Mf treated in vitro with 10-7 M ACR; TNP-Mf ACR & NM - Mf treated with both 
metabolites. 
CBA/J mice were injected i.v. with 1x106 TNP-substituted Mf . Seven days after TNP-Mf injection the mice 
were tested for CHS reaction which is expressed in units x 10-2 mm ± SD. The negative values (ear swelling 
in control, unimmunized  mice) were substracted from experimental values. The statistical significance (a 
posteriori Bonferroni test): Group A vs. Groups B, C, D, E p<0.001. Each group consisted of five mice. 
Table 2. Immunognecity of oil-induced peritoneal macrophages untreated or treated in vivo 
with 50 mg/kg CY or in vitro with acrolein (ACR) or mechloretamine (NM). 
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3.3 The phenotypical differences between functionally differentiated macrophages 
estimation of activity IL-6 and a heterogeneity of - and - naphtyl acetate esterase 
isoenzymes 
Some differences were shown when a population of  different immune functions  were 
tested by unspecific esterase activity, which is  regarded to play a role in intracellular 
processing and trafficking of antigen (Czajkowska et al. 1995). In these experimental 
works we tested two different, but phenotypically indistinguishable macrophage clones 
59 and 63 obtained from Martin Dorf and coworkers from Harvard University, Boston, 
MA. Both are adherent and phagocytic,  produce IL-1 and IL-6 and constitutively express 
a number of identical cell surface markers, including Ia. However they differ functionally 
and while clone 59 presents antigen to Th1 lymphocytes, clone 63 induces suppressor T 
lymphocytes. These obvious functional differences in antigen presenting capacities 
between the seemingly phenotypically identical cell lines were  identified by us in testing 
them for activity of nonspecific - and - naphtyl acetate esterase isoenzymes and 
secretion of IL-6 in case of cell lines stimulated with mechloretamine (NM)– the alkylating 
agent relating to cyclophosphamide. The isoenzymatic patterns of -esterase express 
strong differences in line 59 treated with MN in comparison to background non-activated 
cells. In line 59, NM treatment increases the heterogeneity and activity of esterase in both 
pH 7.5 and pH 5.8. In contrast to line 59 no differences in the isoenzymatic pattern of 
esterase in NM-treated and untreated 63 line cells were found. The -esterase activity 
was also tested but no significant differences were found between untreated and MN-
treated cell lines. 
The results in Table 3 show that CHS inducing clone 59 produces little IL-6 and NM does 
not activate its production in comparison to basal activity. In contrary clone 63 is a high 
producer of IL-6 and stimulated by NM.  
 
Groups 
Clone 59 
IL-6 [ng/mL] X ± SD 
Clone 63 
IL-6 [ng/mL]  X ± SD 
Mf 62 ± 9.6 111 ± 9.3 
Mf & NM 10-6 M 27 ± 4.3 358 ± 3.1 
Mf & NM 10-8 M 35 ± 4.7 226 ± 1.5 
Mf & NM 10-10 M 21 ± 5.5 209 ± 2.1 
2x107 Mf were treated with NM at concentrations from 10-10 to 10-6 M for 40 min at 00C then thoroughly 
washed out from NM with phosphate buffered saline (PBS). Cells cultured in RPMI 1640 medium 
supplemented with 5% fetal calf serum (FCS) at concentration 106 Mf per mL in 24 wells flat bottom 
plates at 370C at 5% CO2. The concentration of IL-6 was estimated in bioassay with B9 cell line with 
(data not shown, but all results were estimated less than 2ng/mL) or without mAb anti-IL-6 and 
expressed in ng/mL. 
Table 3. The production of IL-6 by Mf cell line 59 and 63 treated with different concentration 
of nitrogen mustard  
Our experiments show that two macrophage lines differ in isoenzyme patterns such that  
and esterases of line 59 which induces immunity, are more heterogeneous than esterase of 
line 63, which induces suppression. Both cell lines, when non activated with NM however 
www.intechopen.com
 The Influence of Cyclophosphamide on Immune Function of Murine Macrophages 
 
149 
produce comparable amounts of IL-6 (Czajkowska et al. 1995). We have shown previously 
the peritoneal macrophages (Bryniarski et al. 1996), like line 63 cells, when tagged with the 
antigen, induce T suppressor cells, however, when treated with NM, a pharmacological 
derivative of cyclophosphamide, produce high amounts of IL-6, also change their functional 
(suppressive) properties to activation the hapten specific CHS immune response (Bryniarski 
et al. 2009).  
It was also shown that NM, changed the isoenzyme pattern in line 59, which was 
accompanied by somewhat decreased production of IL-6, while esterases of line 63 were not 
affected by NM, which however activated the production of IL-6. NM, like other alkylating 
factors, binds covalently and non-selectively to variety of molecules including amino acids, 
proteins and DNA. Since the Mf were incubated with NM at 00C the possibility of its 
intracellular penetration was negligible and we presume that under such condition NM 
binds mainly to cell surface proteins. We suggested that the translation of intracellular 
membrane signal acts in a different way, which can result in a different production of IL-6 
by line 59 and 63 cells and their isoenzyme patterns after NM stimulation (Czajkowska  
et al. 1995).  
3.4 Proinflammatory cytokine secretion by functionally different subpopulation of Mf 
treated with CY or its derivatives ACR or NM   
CY influence on the cytokine releasing activity by the functionally different 
subpopulation of macrophages was examined by Marcinkiewicz and Bryniarski 
(Marcinkiewicz et al. 1994 and Bryniarski et al. 1996 & 2009). They have shown that low 
dose of CY treatment activates Mf to production and secretion of mainly IL-6 while 
simultaneously diminish TNF- and IL-1 production (Marcinkiewicz et al. 1994). The 
strong activation of IL-6 production was observed in case of peritoneal macrophage 
stimulation with mechloretamine (NM) the analogue of nitrogen mustard (Bryniarski et 
al. 1996). This is a common phenomenon which is observed in NM-treated oil-induced 
and thioglycolate peritoneal macrophages obtained from different mouse strains (CBA/J, 
Balb c, C57/BL6 and SWISS) and tested in bioassay with IL-6 dependent B9 cells as well 
as in IL-6 ELISA assay (Bryniarski et al. 1996 & 2009).  
3.4.1 Production of cytokines by control Mf or Mf from animals treated in vivo with CY 
or Mf treated in vitro by its metabolites 
Control Mf or Mf from CY-treated animals (50 mg/kg) or Mf incubated in vitro with ACR 
(10–7 M) or NM (10–6 M) were cultured for 24 or 48 h in RPMI 1640 medium and the 
production of five different cytokines was measured in the resultant supernatants by ELISA. 
These results are shown in Table 4. Mf from CY treated animals (Group B) and Mf treated in 
vitro with NM (Group D) showed an increased production of  pro-inflammatory IL-6 and IL-
12, and a decreased production of anti-inflammatory IL-10 and TGF- cytokines compared 
to the control group (Group A). Mf treated with ACR (Group C) manufactured more IL-6 
and less TGF- than control cells (Group A), but the production of IL-12 remained 
unchanged. Treatment with CY or its derivatives did not influence TNF- production 
although in Group B, there it was somewhat lower than in the control group. 
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Cell cultured 
Cytokine production [pg/ml]
TNF-ǂ IL-6 IL-10 IL-12 TGF-ǃ 
A Mf 250  5 283  7 61  3 213  3 109  2 
B Mf CY [50 mg/kg] 182  4 467  4 22  4 455  14 50  4 
C Mf ACR [10-6 M] 287  21 982  25 33  2 167  10 33  3 
D Mf NM [10-7 M] 245  30 1500  100 47  4 460  28 59  17 
Five x105  control Mf or cells from cyclophosphamide-treated animals (Mf CY) or Mf treated with 
acrolein (Mf ACR) or nitrogen mustard (Mf NM) in vitro (for details see legend to Table 3) were cultured 
in 1 ml of RPMI 1640 medium supplemented with 5% FCS for 24h (TNF-ǂ and IL-6) or 48h (other 
cytokines) and concentrations of cytokines were measured by ELISA assays. Table 2 shows the results 
of one representative experiment out of three as the mean of three estimations ± SD. 
Table 4. Cytokine production by macrophages (Mf) from naïve mice, or animals treated with 
cyclophosphamide (CY) in vivo or acrolein (Mf ACR) or nitrogen mustard (Mf NM) in vitro.  
3.4.2 High tolerogenicity of TNP-Mf in vivo can be reversed by administration into 
recipients of anti-IL-10 and/or anti-TGF- mAbs 
Since inefficient immunogenicity of administered intravenously control TNP-Mf as 
compared with CY-treated cells may be due to the different cytokine sets that they produce, 
we injected these cells into recipients that simultaneously received an i.v. injection of 500 μg 
of anti-IL-10, anti-TGF- or a mixture of both antibodies. The CHS reaction was measured 7 
days later. Figure 3  shows that TNP-Mf 
 
CBA/J mice were injected i.v. with 1x106 TNP substituted Mf (groups A, C, D and F) or TNP-Mf CY 
(groups B, E, G). In the groups C and E the mice simultaneously received i.v. 500 g of anti-IL-10 mAb 
and in group D, 500 g anti-TGF mAb, and in groups F & G both mAbs were given. Seven days later 
the CHS response was measured (see legend to Table 2). Statistiacally significant (a posteriori 
Bonferroni test) Group A ve groups B, C and F p<0.002; group A ve groups E and G p<0.001; Group B 
ve groups C, F and G NS; group B ve D p<0.02 
Fig. 3. Tolerance induced by intravenous injection of TNP-Mf can be reversed by 
simultaneous administration of anti-IL-10 and/or anti-TGF- mAbs. Comparison with in 
vivo CY treatment (50 mg/kg) of TNP-Mf (TNP-Mf CY) combined with administration with 
mAbs anti-IL10 or/and anti-TGF-. 
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obtained from naïve donors were non-immunogenic (Group A) but from CY-treated donors 
(Group B) induced CHS response, while animals treated with anti-IL-10 alone (Group C & E) 
or together with anti-TGF- (Group F & G) from both donors produced a significant CHS 
reaction. Anti-TGF- alone (Group D) had no influence on the level of the CS reaction.  
3.5 Production of the reactive oxygen intermediates by Mf CY or macrophages treated 
with low doses of ACR or NM  
The testing of innate immune response mediated by macrophages can be estimated by 
reactive oxygen intermediates (ROI’s) production. We use the luminol-dependent 
chemiluminescence as a measure of activity in Mf stimulated by opsonized zymosan 
particles. Figure 4 shows that Mf from animals treated with 20 or 50 mg/kg of CY produce a 
significantly increased level of ROI’s while the dose of 100 mg/kg remains without effect 
and 200 mg/kg diminished the production of ROI’s below the control level. A marked 
increase of ROI’s level was induced by in vitro incubation Mf in a low concentration of NM 
(10-7 or 10-6 M) while 10-5 M had a slightly inhibitory effect. ACR at concentration  10-7 M and 
10-6 M had no effect when compared with control Mf, whereas 10-5 M was inhibitory.  
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Production of reactive oxygen intermediates (ROI’s) by macrophages is dependent upon the dose of 
cyclophosphamide (CY) used to treat donors. The highest activity is observed with doses 20-50 mg/kg. 
The higher dose of CY (200 mg/kg) decreases ROI’s production by Mf in comparison with control cells 
(Mf). The low concentration of nitrogen mustard (NM) used to treat Mf increases the production of ROI’s 
to a similar level as in vivo treatment of Mf–donors with CY (50 mg/kg). Treatment by 10-5M NM was 
slightly inhibitory (results not shown). Treatment of Mf with acrolein (ACR) (10-5-10-7 M) reduces the 
secretion of ROI’s in a dose dependent manner in comparison to the control group (Mf). Zym – zymosan 
Fig. 4. Influence of in vivo treatment with cyclophosphamide (CY) and in vitro treatment 
with nitrogen mustard or acrolein on the production of reactive oxygen intermediates 
(ROI’s)by murine peritoneal Mf. 
3.6 Testicular macrophages (TMf) and their immune response in the reaction with CY  
Residual testicular macrophages (TMf) that are present in interstitial tissue of male gonads 
are regarded as  essential cells for male reproductive function involved in the regulation of 
hormonal balance in the testis. TMf by released products and also directly by cell-to-cell 
contacts participate in the process of steroidogenesis by Leydig cells. They also influence the 
behavior of Sertoli cells by releasing mediators  and regulate spermatogenesis in testis. 
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Apart from that function TMf play an important role in their functional contribution of 
anatomical blood-testis barrier formed by Sertoli cells (Bryniarski et al 2004).  
3.6.1 Induction of contact hypersensitivity by TMf and effect of CY-treatment 
Similarly to peritoneal macrophages testicular macrophages can be purified by glass 
adherence or fractionation on discontinuous gradient (Bryniarski 2004). Results in Table 5 
show that TNP substituted TMf  (TNP-TMf) when injected i.v. into naïve recipient induce 
unresponsiveness since the following PCL skin sensitization fail to induce CHS reaction 
(group B), but TNP-TMf obtained from donors treated with low dose of CY under the seen 
conditions express strong CHS reaction comparable with control mice actively immunized 
with PCL (group C ve group A).  
 
Groups 
Cells injected i.v. before 
PCL sensitization 
PCL 
sensitization 
CHS reaction in TMf 
recipients in units of swelling 
x 10-2 mm 
A No cells injected + 8.2  1.25 
B TNP-TMf + 2.5  0.80 
C TNP-TMf (50 mg CY) + 7.5  1.54 
Purified TMf obtained from CY-untreated (group B) or CY-treated donors (group B) when substituted 
with TNP hapten (TNP-TMf) were injected i.v. into mice. Seven days later all TMf recipients and naïve 
mice (group A) were skin sensitized with 5% PCL and 4 days later challenged on ear skin with 0.4% PCL. 
24 h later CHS ear swelling response was measured with engineers micrometer and results expressed in 
units of swelling x 10-2mm. Statistics: group A ve group B p<0.001, group B ve group C p<0.01. 
Table 5. Testicular macrophages (TMf) from cyclophosphamide-treated mice do not induce 
suppressor cells in contrast to non-CY treated donors. 
Our further experiments show that the tolerogenic activity of TNP-TMf is mediated by the 
high cytokine secretory activity mainly TGF-. This cytokine is a very basic tool for 
functional strategy of TMf within testis and generates the state of organ as immune 
privileged site.  
The methods used by us for obtaining enriched populations of TMf form mixture of 
testicular interstitial cells lead to separation of TMf into two functionally different cellular 
fractions – low density (fractions between interfaces of Percoll gradient  21/27 – 33/39) and 
high density (over 39/45). Low density fraction produces significantly more TGFthan 
heavier cells and are CY-sensitive, while high density cells are not (Bryniarski et al. 2004). 
Our later experiments show that elimination of TGF- activity by injection of anti-TGF- 
mAb, but not anti-IL-10 mAb completely removed unresponsiveness obtained in TNP-TMf 
recipients after i.v. injection. The other adequate results implementing experiments with 
anti-TGF- mAbs are shown in our paper (Bryniarski 2004).  
Our experiment with TMf shows that injected intravenously induced CHS response in 
recipients pre-treated with CY. We found them also actively presenting corpuscular antigen 
(SRBC) in humoral response (Bryniarski et al. 2004). Again the low density subpopulation of 
TMf  failed to induce CHS when injected i.v. into recipients, but in fact induced the state of 
www.intechopen.com
 The Influence of Cyclophosphamide on Immune Function of Murine Macrophages 
 
153 
tolerance in which subsequent skin application of hapten did not lead to development of 
contact sensitization. More interestingly, pretreatment of TMf donors with CY made the 
whole TMf population immunogenic. The mechanisms of action of CY are not cleared, but it 
has been argued that CY metabolites bind to sulfhydryl groups on antigen presenting cells 
(APC) changing their function (Bryniarski et al. 2004).  
4. Discussion  
Our results show that cyclophosphamide in vivo and both its metabolic highly reactive 
alkylating products --unsaturated aldehyde acrolein (ACR) and nitrogen mustard a 
derivative of phosphoramide mustard second metabolic agent formed in CY metabolism, 
activate TNP substituted Mf that leads to activation of CHS reaction mediated by Mf and 
hapten specific Th1 lymphocytes. We are tempted to suggest that this activity is mediated by 
the net of different proinflammatory (TNF-, IL-1 IL-6) and suppressory (IL-10 and TGF- 
cytokines secreted by Mf which can uncovering TNP-specific immunization activated by TNP 
substituted Mf and change their potential from inhibition of unresponsiveness (untreated Mf) 
into Mf immunogenicity (treated with CY or with CY metabolites).  
4.1 CY and its action on CHS  
Low dose of CY activates mainly of subpopulation of oil- or thioglycolate- induced 
peritoneal macrophages which are able to present hapten and subsequently activate trigger 
of Th1 mediated immune CHS response and diminishes the bioactivity of high density 
subpopulation of macrophages. That subpopulation induces specific immunologic 
unresponsiveness as a result of activating a network excess of efferent suppressor cells and 
mainly cooperates with T suppressor CD8+ hapten specific cells (Treg) and mediates the 
hapten specific tolerance. (Szczepanik et al. 1993; Marcinkiewicz et al. 1994, Bryniarski et al. 
2004 & 2009). The question arises as to how treatment with ACR or NM converts tolerogenic 
Mf into immunogenic Mf. One possibility is that these CY metabolites disrupt the function 
of the Mf subpopulation that induces Treg cells. Alternatively they can enhance the activity 
of Mf subpopulation responsible for the induction of Th1 cells that mediates CHS reaction. 
Finally these two possibilities are not mutually exclusive and the increased production of IL-
12 and IL-6, and the simultaneously decreased production of anti-inflammatory IL-10 and 
TGF- cytokines, make  these later assumptions most likely.  
4.2 CY regulates cytokine network released by Mf  
One of the most strongly expressed of CY and their derivatives treatment of macrophages is 
the activation of IL-6 production (Bryniarski 1996, 2009) . Our results do not address directly 
the questions by which mechanisms NM modifies the macrophages to produce more IL-6. 
IL-6 gene expression can be induced by a variety of physiological (cytokines, growth factor, 
bacterial products) and non-physiological stimuli (certain toxins, medicaments, 
prostaglandin E1), by at least three different signals pathways (diacyloglycerol, cAMP- and 
Ca2+- activated pathways). At the DNA level three functional promoter domains were 
described in conserved region of IL-6 promoter (MRE, NF-IL6 and NFB). Exactly how 
transduction pathways are assigned seems unknown with the possible exception of protein 
kinase C signal which seems to focus on MRE region (Bryniarski et al. 1996). Since NM 
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binds to both DNA and proteins, it could stimulate IL-6 production directly by alkylating 
any domain of promoter region, or indirectly, by the alkylation of cell surfaces or by both 
mechanisms simultaneously.  
IL-6 is one of the major mediators of the immune response, with pleotropic and sometimes 
opposed effects on many different targets. It has been shown for instance that IL-6 enhances 
the cytotoxic activity of NK cells, thus may potentially augment the host defenses and 
contribute to anti-tumor effects of alkylating agents. Nonetheless, in case of the IL-6 
dependent tumours like myelomas or plasma cell leukemias increased IL-6 level could be 
deleterious. The increased production of IL-6 may be responsible for observed paradoxical 
effects of CY which under certain conditions enhances, rather than suppresses both the 
humoral and cell mediated immune responses (Bryniarski et al.1996). 
Apart from the influence of CY and its metabolites on the IL-6 production the inhibition of 
IL-10 and TGF- production by macrophages was also observed. The results presented 
above in Table 4 and Fig.3 clearly suggest that the state of tolerance or unresponsiveness 
observed after TNP-Mf i.v. injection seems to be mediated by the network of pro- and anti-
inflammatory cytokines secreted from macrophages and also tentatively delivered by 
natural regulatory cells. It is highly unlikely that low concentration of cytokine metabolites 
(10-7 and 10-6M) have a direct cytotoxic effect on the Treg-inducing Mf since the cell viability 
remains unchanged during 24 h culture. Our interpretation is also supported by finding that 
shifting the balance between pro- and anti-inflammatory cytokines allows for deliberate 
manipulation of the outgoing response. IL-10 and TGF-, which are anti-inflammatory 
cytokines, inhibit the activity of Th1 cells and Mf and down-regulate their function. As 
shown in Figure 3, administration of anti-IL-10 and/or anti-TGF- mAbs into animals which 
received non-immunogenic TNP-Mf restores their immune potential although to different 
degrees. It indicates that the key suppressive cytokine is IL-10, a finding that is supported by 
other groups (Bryniarski et al. 2009). In a symmetrical situation, as we have shown 
previously, administration of anti-IL-12 antibodies inhibits the function of immunogenic 
TNP-Mf in vivo (Bryniarski et al. 2009). The increased production of IL-12 and IL-6 by 
macrophages indicates that the cell surface signal delivered by ACR or NM activates the 
transcription factor NF-B required for the release of inflammatory cytokines (Bryniarski et 
al. 2009). As reported by other groups, ACR, when allowed free access to the interior of the 
cell, can either block or enhance the activity of NF-B in alveolar macrophages depending 
on the design of cell treatment (Bryniarski et al. 2009). 
4.3 CY modulates oxygen radicals formation by macrophages  
Our results indicate that CY upregulates not only the specific immune response, by 
converting non-immunogenic (tolerogenic) Mf into antigen-presenting cells but also 
positively influences a typical parameter of innate immunity – production of oxygen 
radicals. In up-regulating the immune function of Mf, ACR and NM had much the same 
effect. This was however not the case with regard to the production of ROI’s by these cells. 
Using the low concentrations of metabolites, NM was highly stimulatory while ACR did not 
influence the formation of oxygen radicals above the level observed in control Mf (high 
concentration of both metabolites were inhibitory). One possibility is that the ACR and NM 
bind to different targets on the cell surface. NADPH oxidase catalyzing the generation of 
ROI is composed of several cytosolic and membrane-bound proteins which, after the cell 
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receives a proper signal (e.g. phagocytosis), translocate to form an active enzyme. We 
propose a possible explanation that under our experimental conditions, ACR, in contrast to 
NM, does not bind efficiently to important docking proteins to trigger the increased 
production of ROI. Conflicting results regarding ROI production were also published by 
other groups. Some reports describe the inhibitory activity of ACR, and others indicate an 
increased production of radicals. In effect, one can conclude that experimental conditions 
were the key (Bryniarski at al. 2009). 
Our experimental data showed that untreated and in vivo CY treated populations of 
peritoneal macrophages produce the similar level of nitrogen oxide (Marcinkiewicz et al. 
1994) which does not allow to speculate on its function in the immune regulatory system 
mediated by macrophage stimulated with CY.  
4.4 Immunomodulation in chemotherapy with low doses of CY 
Our data show that chemotherapy by CY or its products may activate the immune system 
by modulating cytokine networks and activation of Mf. This may lead to an enhancement of 
antigen-specific cell mediated immunity but also to activation of mechanisms of innate 
immunity mediated by Mf, like the production of ROI. Additionally, in animal models 
derivatives of different mustards led to decreased secretion of IL-10 and TGF- by tumor 
cells and to their elimination. These and other similar experiments in humans support the 
notion that, at a correct dosage, CY and its metabolites can be a promising accessory tool in 
anti-tumor therapy. 
The mechanism of CY influences macrophage immune function in as was shown previously 
in case of peritoneal Mf and TMf and seems to be the effect of network of different related 
factors. The analysis shows as  the most important the influence of CY on the secretory 
activity of Mf which is the inhibition of IL-10 (in case of peritoneal Mf) and TGF- (mainly in 
case of TMf) with parallel activation of proinflammatory cytokines secretion mainly IL-6, 
and to a lesser degree IL-12. Both cytokine signals lead to activation of antigen presentation 
in Mf. The other important factor mediated by CY treatment is an influence on the activation 
of a cell surface markers expression responsible for uptaking antigen into APC (FcR I, 
FcRII, CD23 – FcRII/III) and their following presentation to T lymphocytes 
subpopulations (CD80/CD86, MHC class II, CD14-LPS receptor).  
4.5 Influence of CY on testicular macrophages  
Although our experiments indicate that in the testis – immune privileged organ – some 
subpopulations of Mf are potentially able to present antigen if they would sneak through 
the blood-testis barrier, they also suggest how this potential activity is under control of other 
Mf and Sertoli cells. Our previous observations have shown that TMf are poor producers of 
oxygen radicals and nitric oxide both involved in the mechanisms of natural immunity 
which may be an evolutionary adaptation to diminish the risk of DNA mutations during 
spermatogenesis. Additionally we showed that specific immune responses controlled by the 
male gonads minimize the risk of development of autoimmune reactions and are potentially 
deleterious to testicular functions (Bryniarski 2004). Testicular Mf are good producers of 
TGF-, which allows them to play an important  functional population of testicular 
interstitial tissue  cells that preserves state of tolerance in testes an immune privilege organs. 
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That state of tolerance eliminates the cellular immune response from the testis and in 
consequence makes an extremely dangerous the viral infection as well as in malignances 
taking place in testis. CY treatment often change TMf activity from unresponsiveness into 
actively antigen presenting cells which in consequence help to undertake anticancer 
response but also often can leads to activation an  autoimmune response and immunological 
infertility as a consequences of chemotherapy.  
5. Conclusions  
The influence of CY on Mf can be summarized as a sum of several different mechanisms 
mediated by macrophages such as secretion of a specific pattern of cytokines and enhances 
expression of cell surface markers that can stimulate antigen presenting function by 
macrophages and last not least production of ROI’s. On the other side there are several 
observations that low dose CY treatment has a direct influence of the different regulatory 
cells in immune system. One of them is a negative activation of CD8+ T lymphocytes leading 
to elimination of their effector mediators - suppressor cytokines secretion mainly TGF- and 
IL-10, which negatively regulate the cellular immune response, but do not express any 
negative effect of humoral response. That state of abrogation of unresponsiveness is also 
observed experimentally when the TNP-substituted Mf obtained from oil-induced donors 
are injected into CY treated recipients of cells (see Figure 5) group C. In that case instead of 
unresponsiveness expressed by control group (group A) strong CHS response appears 24 h 
after challenge. This phenomenon clearly shows the influence of CY on the suppressor 
network of T reg cells. This also clearly shows that CY-manipulation leads to manifold 
effects in which manifold can be described as wiped out or misdirected. In the literature 
there are two papers suggesting depletion activity of CY on Treg CD4 CD25 T lymphocytes 
and Treg CD4 CD25 FoxP3+ lymphocytes (Ghiringhelli et al. 2004 & Zhao et al. 2010)  
 
1x106 TNP substituted Mf (groups A and C) or TNP-Mf CY (groups B and D) were injected i.v. into 
naive (groups A and B) or treated with low dose of  CY  CBA/J mice. Seven days later the CHS 
response was measured (see legend to Table 2). Statistical significance (a posteriori Bonferroni test) 
Group A ve groups B, C and D p<0.001. 
Fig. 5. Alleviation of suppression of contact sensitivity response induced by low dose 
treatment with cyclophosphamide applied either to macrophage donors or recipients. 
www.intechopen.com
 The Influence of Cyclophosphamide on Immune Function of Murine Macrophages 
 
157 
A single administration of low dose of CY (50 mg/kg) into either donors or recipients 
restores the ability of Mf to induce significant CS reaction as a result of: i.) elimination of 
suppressive properties of Mf; ii.) and/or depletion of population of regulatory T cells in 
recipients or iii.) elimination of their suppressive activities. In vitro studies with metabolites 
of CY in contrast to studies in vivo allow identifying the factors which express direct action 
on selected populations of cells in contrary to experimental research in vivo which is able to 
identify parallel with direct also indirect effects of cyclophosphamide action on other than 
macrophages cell populations ( T reg cells) that may change and modulate the activity of 
macrophages and their influence on the immune response. We propose the schemes  
which summarize the influence of low doses of CY on the immune response in mice 
(Figures 6a-6c).  
Figure 6 a-c. The network of the CY influence on the macrophage and regulatory T cells in 
mice. 
 
 
 
 
 
* Induction of T suppressor factor (see the reference by Bryniarski et al. 2-nd European Congress of 
Immunology Berlin 2009) 
 
Fig. 6.a. Activation of unresponsiveness in recipients after i.v. injection of TNP substituted 
Mf – lack of CHS reaction. 
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Fig. 6.b. The network of the CY influence on the macrophage and regulatory cells in mice. 
The i.v. injection into naïve recipient of TNP substituted Mf harvested from CY treated 
donors results in a state of  high CHS reaction  24 h after challenge. 
 
Fig. 6.c. The network  of the CY influence on the macrophage and regulatory cells in mice. 
The i.v. injection of TNP substituted Mf harvested from naïve donors into recipients 
previously treated with low dose of CY results in expression of high CHS reaction  24 h after 
challenge with PCL hapten. The activation of CHS is the effect of blocking of natural reg T 
cells or antigen specific Ts cells. 
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